Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVAL-1
2024-512717-41-00Phase 2Completed
- Sponsor
- Viracta Therapeutics, Inc.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of nanatinostat and valganciclovir in Epstein-Barr virus-positive diffuse large B-cell lymphoma, Post-Transplant Lymphoproliferative Disorder (PTLD), extranodal natural killer/T-cell lymphoma (ENKTL) and 2 more, sponsored by Viracta Therapeutics, Inc. Primary endpoint: Objective response rate. Started Jun 2024; status: completed.
02
Drugs
nanatinostatvalganciclovir
03
Conditions
Epstein-Barr virus-positive diffuse large B-cell lymphomaPost-Transplant Lymphoproliferative Disorder (PTLD)extranodal natural killer/T-cell lymphoma (ENKTL)peripheral T-cell lymphoma (PTCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2024-512717-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512717-41-00.